Charles Silberstein
CIK: 0001813117
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NBP
NovaBridge Biosciences
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Silberstein Charles
Silberstein Charles (SEC CIK 0001813117) files insider reports with the SEC as Chief Financial Officer of NovaBridge Biosciences (NBP).
Signal8 holds 1 ownership filing by Silberstein Charles, a Form 3, filed on Nov 2, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Silberstein Charles's filings is in ROCKVILLE, MD.
Other insiders filing for NovaBridge Biosciences (NBP)
- Woo Ian Ying, Director
- Dennis Phillip Andrew, Chief Medical Officer
- Cao Sean Wuxiong, Chief Bus. Development Officer
- Dewhurst Martin William, Director
- Xu Cong Claire, EVP, Clinical Development
- Lenz Robert A., Director